INOVIO PHARMACEUTICALS INC's ticker is INO and the CUSIP is 45773H201. A total of 92 filers reported holding INOVIO PHARMACEUTICALS INC in Q4 2014. The put-call ratio across all filers is 3.63 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,146,828 | -36.8% | 5,518,837 | -27.4% | 0.00% | -33.3% |
Q2 2023 | $3,394,353 | -37.5% | 7,602,133 | +14.9% | 0.00% | -50.0% |
Q1 2023 | $5,427,452 | -58.9% | 6,618,844 | -21.9% | 0.01% | -60.0% |
Q4 2022 | $13,214,292 | +1.4% | 8,470,700 | +12.2% | 0.02% | -6.2% |
Q3 2022 | $13,026,000 | +25.5% | 7,550,849 | +25.9% | 0.02% | +33.3% |
Q2 2022 | $10,377,000 | -47.4% | 5,998,250 | +9.1% | 0.01% | -33.3% |
Q1 2022 | $19,744,000 | -33.9% | 5,499,823 | -8.1% | 0.02% | -28.0% |
Q4 2021 | $29,868,000 | +10.0% | 5,985,533 | +57.8% | 0.02% | 0.0% |
Q3 2021 | $27,157,000 | +40.2% | 3,792,857 | +81.5% | 0.02% | +47.1% |
Q2 2021 | $19,373,000 | +106.2% | 2,089,861 | +106.4% | 0.02% | +88.9% |
Q1 2021 | $9,395,000 | +20.0% | 1,012,403 | +14.4% | 0.01% | +28.6% |
Q4 2020 | $7,831,000 | +137.1% | 884,909 | +210.7% | 0.01% | +133.3% |
Q3 2020 | $3,303,000 | -71.5% | 284,771 | -33.8% | 0.00% | -78.6% |
Q2 2020 | $11,591,000 | +727.9% | 430,100 | +1.3% | 0.01% | +600.0% |
Q4 2019 | $1,400,000 | +228.6% | 424,474 | +103.9% | 0.00% | +100.0% |
Q3 2019 | $426,000 | -59.0% | 208,188 | -41.1% | 0.00% | 0.0% |
Q2 2019 | $1,039,000 | -72.5% | 353,341 | -65.1% | 0.00% | -80.0% |
Q1 2019 | $3,778,000 | -12.0% | 1,012,896 | -5.6% | 0.01% | -16.7% |
Q4 2018 | $4,292,000 | +62.0% | 1,073,086 | +125.2% | 0.01% | +100.0% |
Q3 2018 | $2,649,000 | +313.9% | 476,402 | +191.6% | 0.00% | +200.0% |
Q2 2018 | $640,000 | -56.5% | 163,387 | -47.7% | 0.00% | -50.0% |
Q1 2018 | $1,472,000 | +32.3% | 312,622 | +16.0% | 0.00% | 0.0% |
Q4 2017 | $1,113,000 | -70.1% | 269,501 | -54.2% | 0.00% | -66.7% |
Q3 2017 | $3,728,000 | +114.9% | 587,899 | +165.7% | 0.01% | +100.0% |
Q2 2017 | $1,735,000 | +559.7% | 221,236 | +483.4% | 0.00% | – |
Q4 2016 | $263,000 | -36.3% | 37,921 | -14.3% | 0.00% | -100.0% |
Q3 2016 | $413,000 | -4.8% | 44,267 | -5.7% | 0.00% | 0.0% |
Q2 2016 | $434,000 | +41.4% | 46,925 | +33.1% | 0.00% | 0.0% |
Q1 2016 | $307,000 | -33.7% | 35,264 | -48.8% | 0.00% | 0.0% |
Q4 2015 | $463,000 | +135.0% | 68,831 | +102.5% | 0.00% | – |
Q3 2015 | $197,000 | -77.6% | 33,999 | -68.4% | 0.00% | -100.0% |
Q2 2015 | $879,000 | +2.7% | 107,743 | +2.7% | 0.00% | 0.0% |
Q1 2015 | $856,000 | -40.1% | 104,958 | -32.6% | 0.00% | -50.0% |
Q4 2014 | $1,430,000 | – | 155,798 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
CAXTON ASSOCIATES LP | 784,679 | $643,437 | 0.10% |
Green Alpha Advisors, LLC | 146,300 | $119,966 | 0.08% |
Virtus ETF Advisers LLC | 54,106 | $44,367 | 0.02% |
Cedar Brook Financial Partners, LLC | 104,881 | $86,002 | 0.02% |
PROFUND ADVISORS LLC | 418,749 | $343,374 | 0.02% |
Arlington Capital Management, Inc. | 27,735 | $22,743 | 0.02% |
Hennion & Walsh Asset Management, Inc. | 382,158 | $313 | 0.02% |
Rafferty Asset Management, LLC | 2,647,927 | $2,171,300 | 0.02% |
Brainard Capital Management LLC | 16,666 | $13,666 | 0.01% |
Beck Bode, LLC | 41,218 | $33,799 | 0.01% |